AstraZeneca is experiencing significant revenue growth, primarily driven by its oncology portfolio, which generated over $7 billion in the last quarter. Despite facing legal challenges tied to the indictment of a former executive in China, the company reported an 8% increase in total revenue and is optimistic about reaching its $80 billion revenue target by 2030. The drugmaker is also investing heavily in research and development, including a £15 billion commitment in China, while diversifying its offerings to include a new weight-loss drug.
“Tezspire recorded total revenues of $361.0 million, up 66% year over year, driven by demand growth and launch uptake in multiple markets. AstraZeneca has a partnership with Amgen AMGN for Tezspire.”
“AstraZeneca profit climbs on cancer and heart drug demand https://t.co/Kxdi0VCEnG”
“AstraZeneca's former China head Leon Wang has been formally charged with medical insurance fraud, unlawful collection of personal information and illegal trade, with the case heading to court.”
“AstraZeneca moves oral weight-loss drug into late-stage development.”
“AstraZeneca's playbook to break into the red-hot obesity market rests on improving upon existing medicines, offering competitive prices and leaning on its experience selling products in emerging markets”
“AstraZeneca forecasts steady growth in 2026 on strong cancer drug demand.”
“AstraZeneca expects profit to grow further this year, boosted by sales of its cancer drugs.”
“AstraZeneca sees steady growth ahead on strong cancer drug demand.”
“The quantum computing company has inked partnerships with major players like AstraZeneca for quantum-accelerated computational chemistry and contracts with government agencies, including the Air Force Research Lab.”
“AstraZeneca (AZN) exceeded Street forecasts with its Q4 2025 financials, thanks mainly to its oncology portfolio.”
“AstraZeneca shares added ~2.9% on Tuesday after the Anglo-Swedish drugmaker exceeded Street forecasts with its Q4 2025 financials, thanks mainly to its oncology portfolio.”
“As for Q4 growth drivers, the company recorded $7.0B in revenue from its oncology portfolio, implying ~22% YoY growth thanks mainly to cancer drugs Tagrisso and Imfinzi.”